Accelerated EU Committee Nod for J&J/Genmab's Darzalex
This article was originally published in Scrip
Executive Summary
Janssen-Cilag (Johnson & Johnson) and Genmab's CD38 monoclonal antibody product Darzalex (daratumumab) has been granted the green light for approval in adults with relapsed and refractory multiple myeloma, under an accelerated procedure.
You may also be interested in...
Expanded US Approval Set To Take Janssen’s Darzalex Higher
Janssen’s multiple myeloma therapy, Darzalex, has won an additional US approval for use earlier in the treatment paradigm, building momentum for a product that has already got off to a strong start.
Darzalex March Continues with EU Approval
The latest approval for Johnson & Johnson's monoclonal antibody therapy Darzalex in multiple myeloma keeps the product firmly on course as a much-needed new option in relapsed/refractory patients but competition in the market is hotting up all the time.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.